Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

310
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
310
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

78
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
78
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

336
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
336
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

449
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
449
Classification of Illness01:17

Classification of Illness

9.3K
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk assessment for canine periodontal disease using a hybrid causal Bayesian network.

Frontiers in veterinary science·2026
Same author

Response: "Letter to the Editor: Lessons to Be Learned From the COVID-19 Pandemic: Some Further Ideas".

International journal of public health·2026
Same author

"It's the future, come on!": a think aloud study exploring clinicians' use of knowledge-based AI decision support.

International journal of medical informatics·2025
Same author

What Lessons can Be Learned From the Management of the COVID-19 Pandemic?

International journal of public health·2025
Same author

Early clinical evaluation of a machine-learning system for risk prediction of trauma-induced coagulopathy in the prehospital setting.

Emergency medicine journal : EMJ·2025
Same author

Dynamic Bayesian network models for self-management of chronic diseases: Rheumatoid arthritis case-study.

Computers in biology and medicine·2025

Related Experiment Video

Updated: Mar 26, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.8K

From complex questionnaire and interviewing data to intelligent Bayesian network models for medical decision support.

Anthony Costa Constantinou1, Norman Fenton1, William Marsh1

  • 1Risk and Information Management Research Group, School of Electronic Engineering and Computer Science, Queen Mary University of London, Mile End Campus, Mile End Road, Computer Science Building, E1 4NS London, UK.

Artificial Intelligence in Medicine
|February 3, 2016
PubMed
Summary

This study presents a novel Bayesian network (BN) framework for medical decision support, outperforming existing methods in predictive accuracy and clinical utility. The approach effectively integrates expert knowledge with complex patient data for enhanced risk management and interventional analysis.

Keywords:
Bayesian networksBelief networksCausal interventionCriminologyDecision supportExpert knowledgeForensic psychiatryMental healthQuestionnaire dataSurvey data

Related Experiment Videos

Last Updated: Mar 26, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.8K

Area of Science:

  • Artificial Intelligence
  • Medical Informatics
  • Decision Science

Background:

  • Medical decision support systems often struggle with complex, incomplete, and unstructured patient data.
  • Developing effective Bayesian network (BN) models requires robust methods that can handle data limitations and expert knowledge integration.

Purpose of the Study:

  • To develop a rigorous and repeatable method for building effective Bayesian network (BN) models for medical decision support.
  • To exploit expert knowledge in BN development due to limited data acquisition possibilities.
  • To ensure BN models are suitable for interventional analysis and demonstrate the limitations of data-only approaches.

Main Methods:

  • The study applies recent Bayesian network (BN) developments tailored for expert-driven model building with limited data.
  • A novel, consolidated, and generalized framework is presented, addressing the entire BN model development lifecycle.
  • The method is based on two validated BN models in forensic psychiatry: DSVM-MSS and DSVM-P.

Main Results:

  • The DSVM-MSS model showed competitive to superior predictive performance (AUC 0.708-0.797) compared to state-of-the-art methods (AUC 0.527-0.705).
  • The DSVM-P model demonstrated superior predictive performance (AUC 0.78) against state-of-the-art models (AUC 0.665-0.717).
  • The developed models enhance risk management through intervention and provide improved decision support for complex clinical questions using unobserved evidence.

Conclusions:

  • The developed BN modeling process is applicable to diverse domains requiring large-scale decision analysis with complex information and expert knowledge.
  • The approach challenges decision scientists to prioritize essential information for inference, promoting smarter data utilization.
  • This framework enhances decision support by enabling interventional analysis and addressing complex clinical queries.